Gastroenterology Hub is intended for healthcare professionals working in the Republic of Ireland only.

Personalised care in Crohn’s disease (CD): Vedolizumab Clinical Decision Support Tool (VDZ-CDST), a treatment  decision support tool

Mark Samaan MBBS BSc, Consultant Gastroenterologist at Guy’s and St Thomas’ NHS Foundation Trust

Watch Mark Samaan discuss how he uses the VDZ-CDST in clinical practice to guide treatment decisions in Crohn’s disease (CD). 
Mark Samaan explains how the tool incorporates clinical parameters to help predict response to Entyvio® (vedolizumab) and how it supports decision-making, particularly in cases where multiple treatment choices are being considered.

Adverse Events should be reported to the Pharmacovigilance Unit at the Health Products Regulatory Authority. Reporting forms and information can be found at: www.hpra.ie.  Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

C-APROM/IE/ENTY/0433 | August 2026

You are now leaving the Gastroenterology Hub

You are now leaving the Gastroenterology Hub

Personalised care in Crohn’s disease (CD): Vedolizumab Clinical Decision Support Tool (VDZ-CDST), a treatment decision support tool

Related content

Personalised care in Crohn’s disease (CD): Optimising treatment sequencing

Personalised care in Crohn’s disease (CD): Treat-to-target approaches

Personalised care in Crohn’s disease (CD): Vedolizumab Clinical Decision Support Tool (VDZ-CDST), a treatment  decision support tool